ClinicalTrials.gg
RecruitingNCT07226219Updated Sep 9, 2026

Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease

A Phase 1 interventional study of Extended-Release Methylphenidate in Sickle Cell Disease, Executive Dysfunction and Cognitive Impairment, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by St. Jude Children's Research Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital — 15 open to participants now, 17 under way, none of them phase 3. Anemia, Sickle Cell · St. Jude Children's Research Hospital.

Planned enrollment
7th of 22
72 · median 45
Started
2025
with 2 others
Phase 1
5 of 45
3 open now
Primary completion
2027-07
later than 6 of 16 live
Registered
42nd of 45
by date

Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, this one is the 7th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 6 of the 16 other live ones, and was the 42nd registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

15 of the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects.

The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not.

Primary Objective:

  • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits.

Secondary Objective:

  • Evaluate neurobehavioral and safety outcomes following MPH treatment.

Exploratory Objective:

  • Evaluate decision-making and determinants influencing methylphenidate utilization among caregivers.
Read the detailed description

Children with sickle cell disease (SCD) are at higher risk for executive functioning (EF) deficits, including attention, working memory, and inhibitory control. These deficits are associated with poor academic performance, reduced quality of life, and challenges transitioning to adult healthcare. Despite the effectiveness of stimulant medications like methylphenidate (MPH) in improving EF in the general population and other medical groups, their use in children with SCD is rare.

This is a single-arm, open-label pilot trial conducted at St. Jude Children's Research Hospital. Thirty children with SCD and EF deficits will receive a 4-week course of extended-release MPH (10 mg or 20 mg daily, based on weight). Extended-release methylphenidate will be administered once daily for 4 weeks. The initial dose will be given in clinic, followed by home administration. Adherence will be monitored via weekly video pill counts.

The study will enroll 30 patients aged 8.0 to 17.9 years with SCD and EF impairment, along with 30 caregivers. An additional 12 caregivers who decline participation will be interviewed to assess decision-making and treatment barriers.

Neurobehavioral assessments and side effect evaluations will be conducted at baseline, immediately post-dose, and weekly during the home medication phase. Caregivers will complete rating scales and interviews to assess treatment acceptability and decision-making.

03

Conditions studied

  • Sickle Cell Disease
  • Executive Dysfunction
  • Cognitive Impairment
  • Attention Deficit/Hyperactivity Disorder (ADHD)

Keywords

  • SCD
  • ADHD
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with SCD
  • Enrolled on the institutional protocol: Sickle Cell Clinical Research Intervention Program (SCCRIP)
  • Between the ages of 8.0 and 17.9 years

    *Included if performance measure, rating scale or diagnostic criteria met (within the past 2 years):

  • *Score at or below a Standard Score of 85 (16th percentile) on any 2 out of 4 performance measures:

    • NIH Toolbox Flanker
    • NIH Toolbox List Sorting
    • NIH Toolbox Dimensional Change Card Sort Test (DCST)
    • Wechsler Intelligence Scale for Children (WISC) -5/ Wechsler Adult Intelligence Scale (WAIS)-4 Digit Span Forward (DSF)
  • *Score at or above a T Score of 60 (84th percentile) on any 1 out of 2 parent rating scales:

    • BRIEF-2 Global Executive
    • BASC-3 Attention
  • *Have a documented diagnosis of attention deficit / hyperactivity disorder (any subtype)
  • English as the primary language
  • Research participant and one caregiver willing to participate and provide consent/assent according to institutional guidelines
  • Negative pregnancy test in female participant of childbearing age

Exclusion criteria

Exclusion Criteria:

  • Primary language other than English
  • Score below the 2nd percentile on the Wechsler Abbreviated Scale of Intelligence (WASI)-2 intelligence quotient (IQ) test (ever)
  • Uncontrolled seizures (seizure within the past 6 months)
  • Cardiomyopathy or known congenital structural cardiac defects
  • Stenotic valvular disease, left coronary artery stenosis, or history of myocarditis or pericarditis
  • History of heart arrhythmia including ventricular tachycardia, ventricular fibrillation, supraventricular tachycardia, or concomitant use of medications associated with QT prolongation
  • Two or more prior episodes of priapism
  • Blood pressure >95th percentile at the three most recent visits consecutively (i.e., >95th percentile reading at all three of the most recent hospital visits to St. Jude).

    • If blood pressure is > 95th %ile compared to age-norms on the day of the baseline visit, a repeat blood-pressure reading will be performed both electronically and manually to confirm findings.
  • Stimulant medication within the past two weeks
  • Severe sensory loss
  • Previous adverse reaction to methylphenidate
  • Inability or unwillingness of research participant or legal guardian/representative to give written .
  • Currently prescribed another medication.
  • Diagnosed with sickle cell-hereditary persistence of fetal (HbSHPFH), sickle cell homozygous C (CC), Hb S/N-Baltimore, or other rare genotypes that would preclude the participant from having the classic symptoms of sickle cell disease
  • Currently prescribed any of the following:

    • Phenobarbital (anticonvulsant)
    • Phenytoin (anticonvulsant)
    • Primidone (anticonvulsant)
    • Warfarin (anticoagulant)
    • Antipsychotic medications
    • Selective Serotonin Reuptake Inhibitor (SSRI) medications
    • Tricyclic antidepressant (TCA) medications
    • Vasopressor medications
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Methylphenidate Treatment Group

    All participants in this single-arm pilot study will receive extended-release methylphenidate for 4 weeks. The intervention is designed to evaluate feasibility, acceptability, adherence, and safety of stimulant treatment in children and adolescents with sickle cell disease (SCD) and executive functioning deficits.

    Drug: Extended-Release Methylphenidate

Interventions

  • DrugMethylphenidateStudies of MethylphenidateMethylphenidate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive a weight-based dose of extended-release methylphenidate (0.6 mg/kg/day), rounded to either 10 mg or 20 mg, taken orally once daily for 4 weeks.

    Also known as: MPH

06

What researchers measure

Primary outcomes

  1. Assess feasibility of methylphenidate

    Feasibility is measured by the participation rate (i.e., ratio of those who agree to participate to those approached).

    Time frame: Feasibility is measured during the initial recruitment process for each participant.

  2. Assess acceptability of methylphenidate

    Acceptability is captured by parent- and self-report ratings on the Acceptability of Intervention Measure (AIM).

    Time frame: Acceptability ratings are captured at baseline and after 4 weeks of treatment with methylphenidate.

  3. Assess adherence to methylphenidate

    Adherence is measured through weekly pill counts. The primary adherence outcome is the ratio of the number of pills taken to those dispersed.

    Time frame: Adherence is measured on a weekly basis through 4 weeks of treatment

Secondary outcomes

  1. Behavior Assessment System for Children, 3rd Edition (BASC-3), Parent Report

    Attention, Hyperactivity, and Depression scales are calculated. The investigators will determine the amount and pattern of missing data. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.

    Time frame: Baseline and 4-6 weeks after treatment

  2. Behavior Rating Inventory of Executive Function, 2nd Edition (BRIEF-2), Parent Report

    Global Executive Composite Scale is calculated. The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.

    Time frame: Baseline and 4-6 weeks after treatment

  3. Pediatric Quality of Life Inventory (PedsQL) Sickle Cell Disease modules, Parent Report

    The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.

    Time frame: Baseline and 4-6 weeks after treatment

  4. Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue modules, Parent Report

    The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.

    Time frame: Baseline and 4-6 weeks after treatment

  5. Conners 4th Edition Short Form, Self Report

    The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.

    Time frame: Baseline and 4-6 weeks after treatment

  6. NIH Toolbox Cognition

    Dimensional Change Card Cort, Flanker, Pattern Comparison, Picture Sequence Memory Test, Picture Vocabulary subtests are completed. The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.

    Time frame: Baseline and ~90 minutes after first dose administered

  7. Woodcock Johnson Tests of Academic Achievement, 4th Edition (WJ-IV)

    Math Fluency subtest is completed. The investigator will determine the amount and pattern of missing data for neurobehavioral outcomes. The relative change (defined as (post - pre)/pre)) will be calculated for each outcome and rank these changes to determine sensitivity of the measures. The goal of measuring neurobehavioral outcomes in this pilot trial is to determine how feasible the measures are for the target population and their relative sensitivity to the effects of methylphenidate treatment.

    Time frame: Baseline and ~90 minutes after first dose administered

  8. Measure key safety outcomes using the Side Effects Rating Scale (SERS)

    The investigator will record all adverse effects reported by participants and categorize adverse effects by type and severity based on the Side Effects Rating Scale. The investigator will present summary statistics, including the number of participants experiencing each type of adverse effect, the severity and the overall percentage of participants affected.

    Time frame: Baseline in-clinic assessments followed by remote weekly assessments for 4 weeks

  9. Measure key safety outcomes using the Systematic Assessment for Treatment Emergent Effects

    The investigator will record all adverse effects reported by participants and categorize adverse effects by type and severity based on the Systematic Assessment for Treatment Emergent Effects. The investigator will present summary statistics, including the number of participants experiencing each type of adverse effect, the severity, and the overall percentage of participants affected

    Time frame: Baseline in-clinic assessments followed by remote weekly assessments for 4 weeks

Other outcomes

  1. Evaluate decision-making and determinants influencing methylphenidate utilization among parents

    Semi-structured interviews will be conducted. The interviews will be transcribed and qualitatively coded.

    Time frame: Baseline and 4-6 weeks after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

Of 58 phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2025
First posted
Nov 10, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Aug 1, 2028
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07226219
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Nov 25, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Sep 9, 2026

Study contacts

Andrew Heitzer, PhD
Contact
referralinfo@stjude.org
888-226-4343
Andrew W. Heitzer, PhD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylphenidate

Start the discussion